Adverse reactions were reported in 249 (28.2%) of the 884 patients (including 155 Japanese patients) who received lemborexant in an international phase III study involving patients with insomnia.
Major adverse reactions included somnolence in 95 patients (10.7%), headache in 37 patients (4.2%), and malaise in 27 patients (3.1%). (See Table 6.)